Questions?

REQUEST A MEDICAL SCIENCE LIAISON (MSL)

Questions?

REQUEST A MEDICAL SCIENCE LIAISON (MSL)

Target the Foundational Prostacyclin Pathway When Treating PAH1

According to the COMPERA registry*

83% of patients are at intermediate-low/-high or high risk at first follow-up2

UPTRAVI® (selexipag) is
the ONLY prostacyclin pathway therapy recommended at first follow-up by the evidence-based 2022 ESC/ERS Guidelines for1†:

Intermediate–low-risk patients

Intermediate–high-/high-risk patients
if IV or SC prostacyclin is unfeasible

UPTRAVI® has the highest-class recommendation (Class I, Level B)‡ for sequential dual- and triple-combination therapy to reduce the risk of morbidity/mortality events1

Discover the UPTRAVI® mechanism of action

SEE THE PROSTACYCLIN PATHWAY

*Based on a post hoc analysis of data from the prospective COMPERA registry (N=1655), an ongoing web-based PH registry launched in 2007 that collects baseline, follow-up, and outcome data from patients who receive targeted therapies for PH. Specialized centers in several European countries participate, with ~80% of the patients coming from German PH centers. In this analysis, patients were newly diagnosed with any form of PAH between January 1, 2009, and December 31, 2020. Risk assessment was evaluated at baseline and follow-up. At first follow-up, 17.3% (n=245) were classified as high risk, 37.8% (n=534) were classified as intermediate-high risk, 27.9% (n=395) were classified as intermediate-low risk, and 17% (n=240) were classified as low risk.2

†The 2022 ESC/ERS Guidelines recommend adding UPTRAVI® for patients without cardiopulmonary comorbidities who are at intermediate-low risk despite receiving ERA/PDE5i therapy. In these patients, switching from a PDE5i to riociguat may be considered. In patients who present as intermediate-high or high risk on oral therapies, also consider adding UPTRAVI® or switching from a PDE5i to riociguat if it is not feasible to add IV or SC prostacyclin analogs.1

‡Class I recommendation definition: evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective. Level B evidence definition: data derived from a single randomized clinical trial or large nonrandomized studies.1

COMPERA=Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension; ERA=endothelin receptor antagonist; ERS=European Respiratory Society; ESC=European Society of Cardiology; IV=intravenous; PAH=pulmonary arterial hypertension; PDE5i=phosphodiesterase type 5 inhibitor; PH=pulmonary hypertension; SC=subcutaneous.

References: 1. Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2022‍;‍43‍(‍38‍)‍:‍3618‍-‍3731. 2. Hoeper MM, Pausch C, Olsson KM, et al. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J. 2022;60(1):2102311. doi:10.1183/13993003.02311-2021